期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

luminal B型乳腺癌的生物学特点 被引量：7

原文传递
导出
摘要 乳腺癌为一种分子水平上具有高度异质性的疾病,相同临床分期或病理类型的患者,采用同一治疗方案,其治疗的敏感性及患者的预后存在明显的差异。利用基因组表达谱基因芯片技术进行乳腺癌分子分型,为肿瘤异质性和预后的判断以及个体化治疗提供了重要依据。但由于费用和技术等方面的限制,临床上通常用受体及蛋白表达的检测来代替基因组分型。luminal B型（管腔B型）是指ER/PR阳性,且Ki67≥14%或HER-2阳性的乳腺癌。
作者 王玮 朱丽
机构地区 上海交通大学医学院附属瑞金医院乳腺疾病诊治中心
出处 《中华乳腺病杂志（电子版）》 CAS 2014年第5期47-49,共3页 Chinese Journal of Breast Disease(Electronic Edition)
基金 国家自然科学青年科学基金项目(81102017)
关键词 乳腺肿瘤 分子诊断技术 病理学 临床 预后
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献26

  • 1Park S, Koo JS, Kim MS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry [ J ]. Breast, 2012, 21 ( 1 ) : 50-57.
  • 2Fountzilas G, Dafni U, Bobos M, et al. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel[J]. PIoS One, 2012, 7(6) : e37946.
  • 3E1 Fatemi H, Chahbouni S, Jayi S, et al. Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco[ J]. Diagn Pathol, 2012, 7 : 170.
  • 4Cintra JR, Teixeira MT, Diniz RW, et al. Immunohistochemical profile and clinical-pathological variables in breast cancer[ J]. Rev Assoe Med Bras,2012,58(2) :178-187.
  • 5白鸽,张建清,杨媚,张莉.Luminal A型与Luminal B型乳腺癌的临床病理特征及预后比较[J].实用肿瘤杂志,2012,27(1):55-59. 被引量：11
  • 6Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer [ Jl. J Natl Cancer Inst, 2009, 101 (10) : 736-750.
  • 7董欢,林燕苹,应学翔,何萍青.Ki67、增殖细胞核抗原在不同分子分型乳腺癌组织中的表达及意义[J].中华乳腺病杂志（电子版）,2013,7(2):15-20. 被引量：12
  • 8Jinno H, Matsuda S, Hayashida T, et al. Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes [ J ]. Chemotherapy, 2012, 58 (5) : 364-370.
  • 9余海云,李文萍,郜红艺,张江宇,王颀.新辅助化疗疗效与乳腺癌Ki67、P53表达的关系[J].中华乳腺病杂志（电子版）,2011,5(3):19-24. 被引量：21
  • 10Mazouni C, Rimareix F, Mathieu MC, et al. Outcome in breast molecular subtypes according to nodal status and surgical procedures[J]. Am J Surg, 2013, 205(6) : 662-667.

二级参考文献72

  • 1李宝江,朱志华,王军业,侯景辉,赵进明,张蓬原,姚广裕,王曦,龙浩,杨名添,戎铁.Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义[J].癌症,2004,23(10):1176-1179. 被引量：126
  • 2何振宇,李彪,胡英,管迅行.Ki67在乳腺癌组织中的表达及临床病理分析[J].中国初级卫生保健,2005,19(12):94-95. 被引量：16
  • 3Ogston KN, l~ller ID, Payne S, et al. A new histological grading system to assess response of breast cancer to primary chemotherapy: prognostic significance and survival [J]. Breast, 2003,12(5): 320-327.
  • 4Tan PH,Bay BH, Yip G, et al. Ki67 in breast cancer correlates genes related to apoptosis and 18(3):374-381. Immunohistochemical detection of with transcriptional regulation of cell death[J]. Mod Pathol, 2005,.
  • 5Vincent Salomon A, Rousseau A, Jouve M , et al. Proliferation markers predictive of the pathological response and disease outcomeot" patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy [J]. Eur J Cancer, 2004, 10 (40) : 1502 - 1508.
  • 6Mullerat J, Deroide F, Winslet MC, et al. Proliferation and P53 expression in anal cancer precursor lesions[J]. Anticancer Res, 2003,23 (3C) :2995- 2999.
  • 7Cheang MC,Chia SK,Vodue D, et al. Ki67 index,HER 2 status and prognosis of patients with luminal B breast cancer[J]. Natl Cancer Inst, 2009,101 (10) : 736-750.
  • 8Yoon YJ,Chang HY,Ahn SH,et al. MDM2 and P53 polymorphisms associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection [J]. Cardnogenesis, 2008,29(6) : 1192-1196.
  • 9Nontero S,Guzman C,Vargas C,et al. Prognostic value of cytosolic P53 protein in breast cancer [J]. Tumor Biol,2001,22(5): 337.
  • 10Hensel M, Schneeweiss A, Sinn HP, et al. P53 is the strongest predictor o{ survival in high -risk primary breast cancer patientsundergoing high-dose chemotherapy with autologous blood stem cell support [J]. Int J Cancer ,2002,100(3):290-296.

共引文献46

同被引文献65

  • 1王佳玉,徐兵河,田丽军,王燕.乳腺癌肝转移的临床病程与预后分析[J].中华肿瘤杂志,2006,28(8):612-616. 被引量：12
  • 2Park S, Koo JS, Kim MS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry [ J ]. Breast, 2012, 21 ( 1 ) : 50-57.
  • 3Fountzilas G, Dafni U, Bobos M, et al. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel[J]. PIoS One, 2012, 7(6) : e37946.
  • 4E1 Fatemi H, Chahbouni S, Jayi S, et al. Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco[ J]. Diagn Pathol, 2012, 7 : 170.
  • 5Cintra JR, Teixeira MT, Diniz RW, et al. Immunohistochemical profile and clinical-pathological variables in breast cancer[ J]. Rev Assoe Med Bras,2012,58(2) :178-187.
  • 6Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer [ Jl. J Natl Cancer Inst, 2009, 101 (10) : 736-750.
  • 7Jinno H, Matsuda S, Hayashida T, et al. Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes [ J ]. Chemotherapy, 2012, 58 (5) : 364-370.
  • 8Mazouni C, Rimareix F, Mathieu MC, et al. Outcome in breast molecular subtypes according to nodal status and surgical procedures[J]. Am J Surg, 2013, 205(6) : 662-667.
  • 9Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast- conserving therapy[J]. J Clin Oneol, 2011, 29(29) : 3885-3891.
  • 10Kneubil MC, Brollo J, Botteri E, et at. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction [ J ]. Eur J Surg Oncol, 2013, 39 ( 3 ) : 260-265.

引证文献7

二级引证文献17

中华乳腺病杂志（电子版）
2014年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部